Cargando…

BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers

SIMPLE SUMMARY: Cutaneous melanoma represents the most aggressive form of skin cancer and its occurrence, development, and progression are based on the accumulation of several genetic alterations. BRAF mutations are frequently found in melanoma and targeted therapies against these specific genetic m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castellani, Giorgia, Buccarelli, Mariachiara, Arasi, Maria Beatrice, Rossi, Stefania, Pisanu, Maria Elena, Bellenghi, Maria, Lintas, Carla, Tabolacci, Claudio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452867/ https://www.ncbi.nlm.nih.gov/pubmed/37627054 http://dx.doi.org/10.3390/cancers15164026

Ejemplares similares

Glioblastoma-Specific Strategies of Vascularization: Implications in Anti-Angiogenic Therapy Resistance
por: Buccarelli, Mariachiara, et al.
Publicado: (2022)

Editorial: Cancer stem cell differentiation: A realistic potential therapeutic option?
por: Buccarelli, Mariachiara, et al.
Publicado: (2023)

Melanoma Cell Resistance to Vemurafenib Modifies Inter-Cellular Communication Signals
por: Tabolacci, Claudio, et al.
Publicado: (2021)

Phytochemicals as Immunomodulatory Agents in Melanoma
por: Tabolacci, Claudio, et al.
Publicado: (2023)

Deletion of a Single Lysine Residue at Position 292 of CAMK2A Disrupts Protein Function, Causing Severe Epileptic Encephalopathy and Intellectual Disability
por: Lintas, Carla, et al.
Publicado: (2023)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma()()
por: Kim, Hee Kyung, et al.
Publicado: (2016)

Targeting of the Lipid Metabolism Impairs Resistance to BRAF Kinase Inhibitor in Melanoma
por: Vergani, Elisabetta, et al.
Publicado: (2022)

Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma
por: Savoia, Paola, et al.
Publicado: (2020)

Nicotinamide inhibits melanoma in vitro and in vivo
por: Scatozza, Francesca, et al.
Publicado: (2020)

On exosome functional role in cancer: miR-494 complex regulation in melanoma cells and corresponding exosomes
por: Bellenghi, Maria, et al.
Publicado: (2019)

Advances in Natural or Synthetic Nanoparticles for Metastatic Melanoma Therapy and Diagnosis
por: Arasi, Maria Beatrice, et al.
Publicado: (2020)

Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma
por: Pisanu, Maria Elena, et al.
Publicado: (2018)

Sex and Gender Disparities in Melanoma
por: Bellenghi, Maria, et al.
Publicado: (2020)

Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications
por: Vanni, Irene, et al.
Publicado: (2020)

Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
por: Atzori, Maria Grazia, et al.
Publicado: (2019)

Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma
por: Fattore, Luigi, et al.
Publicado: (2018)

Biomarkers for Diagnosis, Prognosis and Response to Immunotherapy in Melanoma
por: Puglisi, Rossella, et al.
Publicado: (2021)

Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level
por: Sakaizawa, K, et al.
Publicado: (2012)

Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma
por: Gouda, M.A., et al.
Publicado: (2021)

Identification of Dihydrolipoamide Dehydrogenase as Potential Target of Vemurafenib-Resistant Melanoma Cells
por: Tabolacci, Claudio, et al.
Publicado: (2022)

Targeting Melanoma-Initiating Cells by Caffeine: In Silico and In Vitro Approaches
por: Tabolacci, Claudio, et al.
Publicado: (2021)

BRAF Gene and Melanoma: Back to the Future
por: Ottaviano, Margaret, et al.
Publicado: (2021)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

The immune‐related role of BRAF in melanoma
por: Tomei, Sara, et al.
Publicado: (2014)

The immune-related role of BRAF in melanoma
por: Tomei, Sara, et al.
Publicado: (2015)

Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations
por: Heinzerling, L, et al.
Publicado: (2013)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2023)

Oral malignant melanoma: A report of two cases with BRAF molecular analysis
por: SOMA, PIER FRANCESCO, et al.
Publicado: (2014)

Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation
por: Kiniwa, Yukiko, et al.
Publicado: (2021)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

Targeting BRAF for patients with melanoma
por: Arkenau, H-T, et al.
Publicado: (2011)

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
por: Acciardo, Stefania, et al.
Publicado: (2018)

Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice
por: Heinzerling, L, et al.
Publicado: (2013)

Clinical value of early detection of circulating tumour DNA-BRAF(V600mut) in patients with metastatic melanoma treated with a BRAF inhibitor
por: Louveau, Baptiste, et al.
Publicado: (2017)

TNF-alpha and metalloproteases as key players in melanoma cells aggressiveness
por: Rossi, Stefania, et al.
Publicado: (2018)

Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
por: Goldinger, Simone M., et al.
Publicado: (2013)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
por: Gonzalez-Cao, Maria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_td5bhihjeb5qt8pgs9ibco9pun